EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Clinical significance and prospective mechanism of increased CDKN2A expression in small cell lung cancer

Dong-Ming Li, Guo-Sheng Li, Jian-Di Li, Feng Chen, Hong Huang, Wan-Ying Huang, Zhi-Guang Huang, Yi-Wu Dang, Yu-Lu Tang, Zhong-Qing Tang, Wen-Jia Tang, Gang Chen und 1 weitere

Clinical and Translational Oncology · 11.01.2024 · 26 (6) · 1519-1531

DOI: 10.1007/s12094-023-03376-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Oncology, online erschienen am 11.01.2024. Verfasst von Dong-Ming Li und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, The First Affiliated Hospital of Guangxi Medical University, Guangxi Zhuang Autonomous Region, Nanning, People's Republic of…. Hauptthemen laut MEDLINE: Lung Neoplasms, Small Cell Lung Carcinoma, Cyclin-Dependent Kinase Inhibitor p16, Biomarkers, Tumor. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Guangxi Zhuang Autonomous Region Medical Health Appropriate Technology Development and Application Promotion Project, Guangxi Medical University Key Textbook Construction Project, The Guangxi Zhuang Autonomous Region Health Committee Self-Financed Scientific Research Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Although it has been shown that cyclin dependent kinase inhibitor 2A (CDKN2A) plays a significant role in a number of malignancies, its clinicopathological value and function in small cell lung cancer (SCLC) is unclear and warrants additional research.

Methods

The clinical significance of CDKN2A expression in SCLC was examined by multiple methods, including comprehensive integration of mRNA level by high throughput data, Kaplan–Meier survival analysis for prognostic value, and validation of its protein expression using in-house immunohistochemistry.

Results

The expression of CDKN2A mRNA in 357 cases of SCLC was evidently higher than that in the control group (n = 525) combing the data from 20 research centers worldwide. The standardized mean difference (SMD) was 3.07, and the area under the curve (AUC) of summary receiver operating characteristic curve (sROC) was 0.97 for the overexpression of CDKN2A. ACC, COAD, KICH, KIRC, PCPG, PRAD, UCEC, UVM patients with higher CDKN2A expression had considerably worse overall survival rates than those with lower CDKN2A expression with the hazard ratio (HR) > 1.

Conclusion

CDKN2A upregulation extensively enhances the carcinogenesis and progression of SCLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsSmall Cell Lung CarcinomaCyclin-Dependent Kinase Inhibitor p16Biomarkers, TumorHumansPrognosisFemaleMaleKaplan-Meier EstimateROC CurveRNA, MessengerMiddle AgedSurvival RateProspective StudiesAgedCase-Control StudiesClinical Relevance

Stichwörter der Autor:innen

Clinical significanceCyclin dependent kinase inhibitor 2AImmunohistochemistryKaplan–Meier survival analysisSmall cell lung cancer

Substanzen

Cyclin-Dependent Kinase Inhibitor p16Biomarkers, TumorRNA, MessengerCDKN2A protein, human

Autor:innen und Institutionen

  • Department of Pathology, The First Affiliated Hospital of Guangxi Medical University, Guangxi Zhuang Autonomous Region, Nanning, People's Republic of China.
  • Cardiothoracic Surgery, The First Affiliated Hospital of Guangxi Medical University, Guangxi Zhuang Autonomous Region, Nanning, People's Republic of China.
  • Medical Oncology, The First Affiliated Hospital of Guangxi Medical University, Guangxi Zhuang Autonomous Region, Nanning, People's Republic of China.
  • Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Guangxi Medical University, Guangxi Zhuang Autonomous Region, Nanning, People's Republic of China.
  • Department of Pathology, Wuzhou Gongren Hospital, The Seventh Affiliated Hospital of Guangxi Medical University, No.1, Nansanxiang Gaodi Road, Guangxi Zhuang Autonomous Region, Wuzhou, 543000, People's Republic of China.
  • Department of Pathology, The First Affiliated Hospital of Guangxi Medical University, Guangxi Zhuang Autonomous Region, Nanning, People's Republic of China. luhuiping@gxmu.edu.cn.

Förderung

  • Guangxi Zhuang Autonomous Region Medical Health Appropriate Technology Development and Application Promotion Project
  • Guangxi Medical University Key Textbook Construction Project
  • The Guangxi Zhuang Autonomous Region Health Committee Self-Financed Scientific Research Project
  • Guangxi Medical University Student Innovation and Entrepreneurship Training Program Project

Zitieren

APA

Li, D. M., Li, G. S., Li, J. D., Chen, F., Huang, H., Huang, W. Y., Huang, Z. G., Dang, Y. W., Tang, Y. L., Tang, Z. Q., Tang, W. J., Chen, G., & Lu, H. P. (2024). Clinical significance and prospective mechanism of increased CDKN2A expression in small cell lung cancer. Clinical and Translational Oncology, 26(6), 1519-1531. https://doi.org/10.1007/s12094-023-03376-2

Vancouver

Li DM, Li GS, Li JD, Chen F, Huang H, Huang WY, et al. Clinical significance and prospective mechanism of increased CDKN2A expression in small cell lung cancer. Clinical and Translational Oncology. 2024;26(6):1519-1531. doi:10.1007/s12094-023-03376-2

BibTeX
@article{Li2024,
  author = {Li, Dong-Ming and Li, Guo-Sheng and Li, Jian-Di and Chen, Feng and Huang, Hong and Huang, Wan-Ying and Huang, Zhi-Guang and Dang, Yi-Wu and Tang, Yu-Lu and Tang, Zhong-Qing and Tang, Wen-Jia and Chen, Gang and Lu, Hui-Ping},
  title = {Clinical significance and prospective mechanism of increased CDKN2A expression in small cell lung cancer},
  journal = {Clinical and Translational Oncology},
  year = {2024},
  volume = {26},
  number = {6},
  pages = {1519--1531},
  doi = {10.1007/s12094-023-03376-2}
}
Kostenlos starten →